Navigation Links
Alseres Pharmaceuticals, Inc.'s Chairman, Peter Savas, Reviews Company's Progress in its Annual Letter to Stockholders
Date:6/12/2008

or a $7 million fee payable on or before

October 27, 2008. If Alseres exercises this option, the pre-commercial

milestone payments in the amended license agreement will be reduced

from $25 million to $7 million and payable on or before December 31,

2009. In addition, the sales-based royalties in the amended license

agreement will be reduced from 10-12% to 4% for spinal cord injury and

1% for all other indications.

-- In March, Alseres entered into an agreement that provides for the

Company to borrow $5 million from Robert L. Gipson, an existing lender.

The agreement further provides that the Company may borrow up to an

additional $5 million from any existing lender under the agreement on

the same terms and conditions.

We are pursuing a growing number of confidential partnering discussions with leading companies regarding our molecular imaging, our nerve repair and our regenerative therapy programs and assets. Our recent agreement to improve the terms of the Cethrin license may represent a major step forward for Alseres in realizing the full value of our Cethrin spinal cord program and our Rho inhibitor technology platform and, most importantly, may open up key partnering opportunities.

Our primary objective is to bring our promising lead products to market efficiently. Our ability to accomplish our commercialization objective is enabled by an organization that has developed credible relationships with regulatory authorities, world experts and potential partners. In that regard, I am pleased to acknowledge that MIT Professor Robert Langer, a member of our Board and Chairman of our Science and Technology Committee, has been awarded the 2008 Millennium Technology Prize for intelligent drug delivery. The Prize, which is the world's largest for technology innovation, is given by the Technology Academy Finland. Professor Robert Langer's innovations have had a s
'/>"/>

SOURCE Alseres Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine news :

1. Alseres Pharmaceuticals, Inc. to Present at New York Society of Security Analysts Conference
2. Alseres Pharmaceuticals, Inc. Raises $5 Million
3. Alseres Pharmaceuticals, Inc. Complies With NASDAQ Rule Regarding Recently Filed 10-K
4. Alseres Pharmaceuticals, Inc. to Present at The Neurotech Industry Investing & Partnering Conference
5. Alseres Pharmaceuticals to Host 2008 First Quarter Conference Call
6. Alseres Pharmaceuticals, Inc. Reports First Quarter 2008 Operational and Financial Results
7. Vista Partners Initiates Coverage on Alseres Pharmaceuticals, Inc. (Nasdaq: ALSE)
8. Alseres Pharmaceuticals, Inc. Announces 2008 Annual Stockholders Meeting
9. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
10. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
11. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... led by Queen,s University professor Robert Campbell (Ophthalmology) has ... not helpful or necessary., Glaucoma is the most common ... 400,000 Canadians are afflicted with the disease, which is ... enough to damage the optic nerve. The optic nerve ... the brain and is a vital part of vision., ...
(Date:9/18/2014)... release is available in German . ... host strategy not to fight a pathogen tooth and nail, but ... term. One key feature of tolerance is that the disease only ... host carries a high pathogen load. , Roland Regoes, a senior ... this approach to HIV. He set about investigating whether there are ...
(Date:9/18/2014)... It is almost time to park your ... healthier and happier kids. The South Florida Hyundai Dealers ... Annual Miami Children’s Hospital 5K Run/Walk. Its title sponsor ... , The 5K will take place on Saturday August 20th. ... Coral Gables City Hall located at 405 Biltmore Way. ...
(Date:9/18/2014)... Research conducted by a team of ... has documented improved survival in patients with cancerous ... tumors along with stereotactic radiosurgery. , The study was ... (American Society for Radiation Oncology) this week in San ... radiation beams to treat tumors in the brain, delivering ...
(Date:9/18/2014)... and London. (PRWEB) September 18, 2014 ... Computer Aided Engineering software, today announced its new partnership ... be utilizing the CD-adapco simulation tool, STAR-CCM+® in the ... just announced its participation in the 35th America’s Cup ... 35th edition of the America’s Cup is sustainability, the ...
Breaking Medicine News(10 mins):Health News:Withdrawal from the evolutionary race 2Health News:Withdrawal from the evolutionary race 3Health News:South Florida Hyundai Dealers Association Proudly Support the 4th Annual Miami Children’s Hospital 5K Run/Walk this Saturday August 20th in Coral Gables 2Health News:South Florida Hyundai Dealers Association Proudly Support the 4th Annual Miami Children’s Hospital 5K Run/Walk this Saturday August 20th in Coral Gables 3Health News:Allegheny Health Network Study Shows Improved Survival in Patients with Metastatic Brain Cancer Who Undergo Surgical Excision Combined with Stereotactic Radiosurgery 2Health News:Allegheny Health Network Study Shows Improved Survival in Patients with Metastatic Brain Cancer Who Undergo Surgical Excision Combined with Stereotactic Radiosurgery 3Health News:Ben Ainslie Racing Using STAR-CCM+ Simulation Software to Design 35th America’s Cup Racing Boat 2
... studying rare genetic disorders have uncovered insights into ... when cells divide. Focusing on the cohesin complex, ... encircles chromosome pairs, scientists have discovered mutations that ... diseases called cohesinopathies. "We are learning more ...
... Israel; Seoul, South Korea, May 29, 2012 -- The ... enabled an Israeli-South Korean scientific team to conduct a genetic ... B virus (HBV) genotype C2 sequence common in Southeast Asia. ... be used as a model to study the evolution of ...
... Texas For 50 years scientists have been unsure how the ... basic innate immune responses. That mystery has now been solved, thanks ... The answers may help clear the way for a ... such as V. cholerae , but instead disable their defenses ...
... battle: Long after a cancer has been beaten into remission, it ... is unclear. New research led by Weizmann Institute scientists shows that, ... cancer recurrence is in a set of cells that do not ... survive chemotherapy. The findings, which appeared today in the journal ...
... not healthy. However, new research from the University of Copenhagen ... vitamin is not good either. The study is based on ... published in the reputed scientific Journal of Clinical Endocrinology ... calcium reach our bones, thus lessening the risk from falls ...
... , MONDAY, May 28 (HealthDay News) -- Women who work ... increasing their risk for breast cancer, Danish researchers find. ... women who describe themselves as "morning" people rather than "evening" ... of women in modern societies have night shift work," said ...
Cached Medicine News:Health News:Mutations impair childhood growth and development by disrupting organization of chromosome pairs 2Health News:16th-century Korean mummy provides clue to hepatitis B virus genetic code 2Health News:50-year cholera mystery solved 2Health News:Why chemotherapy fails 2Health News:Why chemotherapy fails 3Health News:Too much vitamin D can be as unhealthy as too little 2Health News:Night Shift Might Boost Women's Breast Cancer Risk: Study 2Health News:Night Shift Might Boost Women's Breast Cancer Risk: Study 3Health News:Night Shift Might Boost Women's Breast Cancer Risk: Study 4
(Date:9/18/2014)...   Fruit Street Health (Fruit Street), today ... of funding. The round, which includes ... of individual investors, the majority of whom are prominent ... round are; Houston Cardiology Consultants Partner Asif Ali, ... Rapha Family Medicine Practice Owner Frances Ilozue , ...
(Date:9/18/2014)...  KIYATEC announced today that it has been ... (SBIR) Phase II Contract from the National Cancer ... centers that comprise the National Institutes of Health ... award, KIYATEC will expand its 3D breast cancer ... of cancer therapy strategies: 1) cancer,s interaction with ...
(Date:9/18/2014)... , Sept. 18, 2014  Decision Resources Group finds ... growth factor (VEGF) agent for wet AMD, is equally ... plans as Genentech,s Lucentis, which is the standard of ... care organization (MCO) directors do not identify a clear ... more likely than Lucentis to be listed on tier ...
Breaking Medicine Technology:Fruit Street Health Secures First Round Of Seed Funding Led By Group Of Medical Industry And Technology Leaders 2Fruit Street Health Secures First Round Of Seed Funding Led By Group Of Medical Industry And Technology Leaders 3National Cancer Institute Awards KIYATEC Nearly $2M to Advance Predictive Cancer Diagnostics 2National Cancer Institute Awards KIYATEC Nearly $2M to Advance Predictive Cancer Diagnostics 3Regeneron's Eylea and Genentech's Lucentis Are Equally Likely to be Covered on Commercial and Medicare Advantage Plans for Wet AMD 2Regeneron's Eylea and Genentech's Lucentis Are Equally Likely to be Covered on Commercial and Medicare Advantage Plans for Wet AMD 3
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: